Skip to main content
Clinical Trials/KCT0009036
KCT0009036
Not yet recruiting
未知

Efficacy and Safety Evaluation of Hemoglobin Control by Erythrocyte Stimulate Agent Recommendation Algorithm in Kidney Failure with Renal Replacement Therapy: Multicenter, Prospective, Single Blind, Randomization Control Trials

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the genitourinary system
Sponsor
Yonsei University Health System, Severance Hospital
Enrollment
250
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with end\-stage renal disease who have been on hemodialysis for more than 6 months
  • \- Patients with hemoglobin levels above 8\.0 g/dL and below 14\.0 g/dL
  • \- Patients using or planning to use Darbepoetin alpha
  • \- Adults over 19 years old and under 80 years old
  • \- Patients weighing more than 40\.0 kg and less than 100\.0 kg
  • \- Among the target subjects, patients whose voluntary consent procedure was confirmed after explanation of the clinical trial
  • \- Patients who can collect clinical variables for the past 5 months from the time of study registration required for algorithm operation

Exclusion Criteria

  • \- Patients temporarily receiving hemodialysis due to acute kidney disease
  • \- Patients temporarily undergoing hemodialysis before transplantation
  • \- Patients who have experienced blood transfusion within 3 months of participating in the study
  • \- Patients with serious systemic condition
  • \- Patients with low compliance, e.g., people with mental illness
  • \- Patients withdrew from clinical trials

Outcomes

Primary Outcomes

Not specified

Similar Trials